Professor Jonathan Ledermann is a Consultant Medical Oncologist, lead medical oncologist and the clinical research lead for gynaecological cancers in the North London Cancer Network, specialising in the treatment of gynaecological and colorectal cancers. His other research interests are in clinical trials and he is head of the UCL Cancer Trials Centre, one of the NCRI-accredited national cancer trials centres funded by research grants from Cancer Research UK. Professor Ledermann has developed and led several national and international trials in gynaecological cancer, currently leading two trials with novel drugs in ovarian cancer. 

Professor Ledermann graduated in medicine at UCL and UCH Medical School, subsequently training in medical oncology at UCH, Charing Cross Hospital London, and the Princess Margaret Hospital Toronto, before moving to UCL as a consultant in 1990. 

Professor Ledermann is a member of the NCRI clinical studies group for gynaecological cancers and one of the UK representatives on the GCIG (Gynaecological Cancer InterGroup). He has many publications to his name in the field of ovarian and colorectal cancer, serves on editorial boards for professional journals and is a medical advisor to several pharmaceutical companies. He is an acknowledged international expert in ovarian cancer and has lectured widely on his research.

• Treatment of gynaecological and colorectal cancers
• Ovarian cancer (chemotherapy)

• Gynaecological oncology
• Ovarian cancer (chemotherapy)
• Colorectal cancers

Dr Melanie Powell studied medicine at The Royal Free Hospital and trained in cancer medicine at The Royal Marsden, Mount Vernon and The Middlesex Hospitals. She has been based at St Bartholomew's Hospital since 1998 where she has a particular interest in the treatment of gynaecological, head and neck cancers and radiation for lymphoma and prostate cancer. Her main research interests include improved targeting of radiation therapy with an emphasis on reducing toxicity and potentially increasing cure rates.

Dr Powell is a member of the National Cancer Research Network Gynaecological Cancer Group and sits on The East London and City Research Ethics Committee. In addition, she is actively involved with the teaching of medical students at Barts and The London School of Medicine.

• Gynaecological
• Prostate
• Head and neck cancers
• Lymphoma (chemotherapy and radiotherapy)

• Gynaecological
• Prostate
• Head and neck cancers
• Lymphoma (chemotherapy and radiotherapy)

Dr Danielle Power is a Consultant Clinical Oncologist, based at Imperial College NHS Trust and Honorary Senior Lecturer at Imperial College. She specialises in gastrointestinal cancers, lung, upper gastrointestinal cancers, small cell lung cancer, non small cell lung and other types of lung cancer. She undertook oncology training in London at a range of specialist centres, including the Royal Marsden Hospital, Mount Vernon Cancer Centre, University College Hospital and Hammersmith Hospital.

Dr Power has been awarded a Fellowship of the Royal College of Radiologists. She was also appointed a Consultant and Honorary Senior Lecturer at St Mary’s Hospital and subsequently at Imperial College Healthcare NHS Trust, with specialist interest in oeosphagogastric cancer, lung cancer and thyroid malignancies. She is trained in chemotherapy, immunotherapies, biological therapies and radiotherapy. Including stereotactic radiotherapy and the use of radionuclide therapies. She is also active in teaching, training and is an investigator or co-investigator in a number of clinical trials. In 2017, Dr Power was appointed Clinical Director for Oncology & Palliative Care Services at Imperial College Healthcare NHS Trust.

• Chemotherapy
• Radiotherapy
• Immunotherapy
• Biological Therapy
• Palliative Care

• Oesophageal Cancer
• Thyroid Cancer
• Lung Cancer

Professor Ros Eeles is Professor of Oncogenetics at The Institute of Cancer Research, University of London UK. She trained at The University of Cambridge, UK and St Thomas' Hospital, London. She is a Fellow of the Royal College of Physicians and Royal College of Radiologists (Clinical Oncology Faculty), London UK. She is accredited in Clinical Oncology and has extensive sub-specialist experience in Cancer Genetics.

Professor Eeles' oncological practice is in radiotherapy and chemotherapy for Uro-Oncology. Her cancer genetics practice involves cancer risk assessment, screening advice and management of increased cancer risk in adults for any cancer site. She is also an expert in how the new cancer genetics impacts on treatment decisions. She has edited a specialist textbook on Cancer Prevention and Screening which won the BMA Chairman's award in 2019. She is an author of over 500 original research papers. She has an international standing in Cancer Genetic Clinical Management and research, particularly management of individuals with mutations in the breast/ovarian/prostate cancer predisposition genes, BRCA1, BRCA2 and other genes and genetic predisposition to prostate cancer. She has been on several genetics advisory committees and edited the special edition of Familial Cancer: Cancer Genetics: New Ways of Working which reported on models of delivery of cancer genetics services.

She is a member of the learned societies: ESTRO, ESMO, ASHG, AACR, BAUS, ESHG, ASCO, BSGM and CGG UK

Her outside interests are Opera and Art.

• Clinical Genetics wrt cancer in adults
• Cancer genetics
• Prostate Genetics

• Clinical genetics wrt cancer genetics in adults
• Cancer genetics
• Medical genetics
• Prostate Genetics

Dr Karavasilis is part of the sarcoma team at UCLH, specialising in the systemic treatment of adult patients with various types of sarcomas, including bone sarcomas and GISTs. He is also Assistant Professor of Oncology at Aristotle University of Thessaloniki, Greece and was previously their director of the Medical Oncology.

Dr Karavasilis has a strong interest in clinical and translational research in sarcomas, particularly looking for novel agents for the treatment of this type of cancer. He also has over 15 years’ experience in clinical trials.

• Chemotherapy

• Sarcoma
• Soft Tissue Sarcoma

Dr Ruheena Mendes is a Consultant Clinical Oncologist who specialises in Head and neck cancer, lung cancer, small cell lung cancer, Non-small cell lung and Other types of lung cancer.

• Radiotherapy

• Head and neck cancer
• Lung cancer
• Small cell lung cancer
• Non-small cell lung
• Other types of lung cancer

Dr Rassam Qualified in 1980 from the University of Baghdad. In 1986 he arrived to the UK on a scholarship for post-graduate training in haematology. He trained as a Registrar at the Royal Free Hospital, London and Edgware General Hospital and a Senior Registrar and University of London Lecturer at St Bartholomew’s Hospital, University College Hospital and Hospital for Sick Children at Great Ormond Street. During his time as a senior registrar, he conducted research into immune reconstitution following stem cell transplantation in children with severe combined immune deficiency. He received his Membership of the Royal College of Physicians and the Royal College of Pathologists in 1989 and 1992 respectively and was elected as Fellow of both colleges in 1997 and 1999.

Dr Rassam has a special interest in the management of lymphoid malignancies and in research into the immune mechanisms and therapy of cancer. In 1997 he was awarded The Microscopical Society of Great Britain and Ireland Fellowship to study the technology and isolation of tumour infiltrating lymphocytes (the immune cells against cancer) at Harvard University in the USA. Following his return, he established a research laboratory at Queen Mary’s Hospital to study the role of the immune system in lymphatic cancer and has presented his findings in National and International meetings. Dr. Rassam has continued in his efforts in the world of research as has won a number of prestigious awards.

Dr. Rassam is an active member of the low and high grade lymphoma subgroups of the National Cancer Research Institute (NCRI), the British Society of Haematology, the American Society of Haematology, The UK Waldenstroms Macroglobulinaemia Group and an author on the British Society of Haematology Guidelines in Waldenstrom’s Macroglobulinaemia. He is an examiner and appointment advisory officer for the Royal College of Pathologists. He is the author of a number of National clinical trial proposals. He is also the chairman of the Hemato-Oncology Group in the Kent Cancer Network and responsible for updating the lymphoma and chronic lymphocytic leukaemia (CLL) pathways. He is the National Chief Investigator for the ASCEND study in CLL.

Diseases, Medical Tests and Treatments

• Chemotherapy
• General Haematology
• Haematological oncology
• Lymphoma: Hodgkin and non-Hodgkin
• Myeloma
• Leukaemia

Dr Shibani Nicum is a Consultant Medical Oncologist, specialising in ovarian and other gynaecological cancers and is based at the Oxford Cancer Centre, in addition to seeing private patients at a variety of hospitals, including in London. Dr Nicum is a graduate of Birmingham Medical School and then completed specialist oncology training at the Royal Marsden Hospital in London, before taking up her role in Oxford in 2009. She is the Lead Clinician for the Gynaecology Unit, the Oxford Multidisciplinary Team and the Thames Valley Gynaecology Alliance Group.

She is particularly interested in BRCA mutated cancers and the development of new therapies for individualised care. Dr Nicum was awarded a national grant from Cancer Research UK to undertake laboratory-based research and also awarded a DPhil from the University of Oxford in 2007. She contributes regularly to peer review journals and speaks at conferences. She is also the Gynaecology Research Lead and has responsibility for translating laboratory advances into benefit for patients. This incudes being Chief Investigator for the CRUK OCTOVA trial, the 6MP BRCA trial and the upcoming ICON9 trial in addition to being principal investigator for other novel agent trials. Dr Nicum is a committee member of the UK National Cancer Research Institute Gynaecological Oncology and the Ovarian Cancer Clinical Studies Groups.

• Chemotherapy
• Immunotherapy

• Ovarian Cancer
• Gynaecological Cancers

Dr Wolstenholme works as a Consultant Clinical Oncologist at Barts Health, London's largest NHS Trust. She completed her training at Guys and St Thomas' Hospital and at the Royal Marsden.

She is strongly committed to high quality, individualised cancer care and works closely with a specialist team of colleagues. Her special interests include developing new breast radiotherapy techniques and late effects of cancer treatment.

• Breast Cancer
• Stereotactic Radiotherapy
• Heart Sparing Radiotherapy

• Breast Cancer
• Stereotactic Radiotherapy
• Heart Sparing Radiotherapy